Douglas R. McAndrew, Executive Vice President and Chief Operating Officer - West of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a tax-withholding transaction in Common Stock dated November 4, 2026.
Michael A. Kosuth, Executive Vice President and Chief Operating Officer - East of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a share withholding transaction dated November 4, 2026.
Giovanni Gallara, Executive Vice President and Chief Clinical Services Officer of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, reporting a November 4, 2026 transaction in which shares of common stock were withheld to satisfy tax obligations from a …
Jonathan P. Conser, Executive Vice President, Chief Growth & Customer Officer of Concentra Group Holdings Parent, Inc., reported a disposition of common stock on November 4, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 6, 2026.
John A. deLorimier, Executive Vice President and Chief Information & Technology Officer of Concentra Group Holdings Parent, Inc. (NYSE:CON), reported a change in beneficial ownership of common stock on November 6, 2026, covering a transaction dated November 4, 2026.
Greg M. Gilbert, Executive Vice President, Chief Reimbursement and Government Relations Officer at Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a share withholding transaction dated November 4, 2026.
Matthew T. DiCanio, President and Chief Executive Officer of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a share withholding transaction dated November 4, 2026, to satisfy tax obligations from a restricted stock vesting event.
A Form 4 filed on November 6, 2026 disclosed that Thomas A. Devasia, Executive Vice President, Chief Marketing and Innovation Officer of Concentra Group Holdings Parent, Inc., disposed of 11,806 shares of common stock on November 4, 2026 to satisfy tax obligations arising from …
Director Jason Aryeh filed a Form 4 with the SEC on November 6, 2026, disclosing a sale of Ligand Pharmaceuticals common stock on November 4, 2026.
John Robert Anderson Jr., Executive Vice President and Chief Medical Officer of Concentra Group Holdings Parent, Inc., filed a Form 4 on November 6, 2026, disclosing a tax-withholding transaction on November 4, 2026, in which 13,080 shares of common stock were withheld at $40.90 …